QQQ   332.28 (-0.23%)
AAPL   173.03 (-0.09%)
MSFT   292.71 (-0.26%)
META   179.47 (-0.79%)
GOOGL   121.70 (-0.31%)
AMZN   144.78 (+1.12%)
TSLA   919.69 (-0.89%)
NVDA   188.79 (-0.80%)
NIO   20.91 (-1.83%)
BABA   92.65 (-1.65%)
AMD   100.20 (-0.80%)
MU   63.86 (-1.30%)
T   18.57 (+0.98%)
CGC   3.78 (-1.05%)
F   16.43 (+0.67%)
GE   81.07 (+1.58%)
DIS   124.96 (+0.56%)
AMC   24.81 (+2.48%)
PYPL   102.08 (+0.56%)
PFE   49.86 (+0.22%)
NFLX   245.69 (-1.37%)
QQQ   332.28 (-0.23%)
AAPL   173.03 (-0.09%)
MSFT   292.71 (-0.26%)
META   179.47 (-0.79%)
GOOGL   121.70 (-0.31%)
AMZN   144.78 (+1.12%)
TSLA   919.69 (-0.89%)
NVDA   188.79 (-0.80%)
NIO   20.91 (-1.83%)
BABA   92.65 (-1.65%)
AMD   100.20 (-0.80%)
MU   63.86 (-1.30%)
T   18.57 (+0.98%)
CGC   3.78 (-1.05%)
F   16.43 (+0.67%)
GE   81.07 (+1.58%)
DIS   124.96 (+0.56%)
AMC   24.81 (+2.48%)
PYPL   102.08 (+0.56%)
PFE   49.86 (+0.22%)
NFLX   245.69 (-1.37%)
QQQ   332.28 (-0.23%)
AAPL   173.03 (-0.09%)
MSFT   292.71 (-0.26%)
META   179.47 (-0.79%)
GOOGL   121.70 (-0.31%)
AMZN   144.78 (+1.12%)
TSLA   919.69 (-0.89%)
NVDA   188.79 (-0.80%)
NIO   20.91 (-1.83%)
BABA   92.65 (-1.65%)
AMD   100.20 (-0.80%)
MU   63.86 (-1.30%)
T   18.57 (+0.98%)
CGC   3.78 (-1.05%)
F   16.43 (+0.67%)
GE   81.07 (+1.58%)
DIS   124.96 (+0.56%)
AMC   24.81 (+2.48%)
PYPL   102.08 (+0.56%)
PFE   49.86 (+0.22%)
NFLX   245.69 (-1.37%)
QQQ   332.28 (-0.23%)
AAPL   173.03 (-0.09%)
MSFT   292.71 (-0.26%)
META   179.47 (-0.79%)
GOOGL   121.70 (-0.31%)
AMZN   144.78 (+1.12%)
TSLA   919.69 (-0.89%)
NVDA   188.79 (-0.80%)
NIO   20.91 (-1.83%)
BABA   92.65 (-1.65%)
AMD   100.20 (-0.80%)
MU   63.86 (-1.30%)
T   18.57 (+0.98%)
CGC   3.78 (-1.05%)
F   16.43 (+0.67%)
GE   81.07 (+1.58%)
DIS   124.96 (+0.56%)
AMC   24.81 (+2.48%)
PYPL   102.08 (+0.56%)
PFE   49.86 (+0.22%)
NFLX   245.69 (-1.37%)
NASDAQ:TWST

Twist Bioscience - TWST Stock Forecast, Price & News

$51.07
-2.84 (-5.27%)
(As of 08/16/2022 12:00 AM ET)
Add
Compare
Today's Range
$49.33
$53.89
50-Day Range
$26.20
$56.56
52-Week Range
$25.07
$139.99
Volume
822,580 shs
Average Volume
1.07 million shs
Market Capitalization
$2.88 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$54.00

Twist Bioscience MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
5.7% Upside
$54.00 Price Target
Short Interest
Healthy
10.77% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.42
Upright™ Environmental Score
News Sentiment
0.70mentions of Twist Bioscience in the last 14 days
Based on 10 Articles This Week
Insider Trading
Selling Shares
$654,504 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($4.53) to ($4.67) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.50 out of 5 stars

Medical Sector

1058th out of 1,124 stocks

Biological Products, Except Diagnostic Industry

170th out of 176 stocks

TWST stock logo

About Twist Bioscience (NASDAQ:TWST) Stock

Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company has collaboration agreements with Victorian Clinical Genetic Services; Vivlion GmbH.; Kyowa Kirin Pharmaceutical Research, Inc.; deepCDR Biologics AG; and Centogene N.V to develop advanced sequencing tools. It also has a research collaboration with Boehringer Ingelheim International GmbH to use proprietary antibody libraries to discover therapeutic antibodies against multiple targets. Twist Bioscience Corporation was incorporated in 2013 and is headquartered in South San Francisco, California.

Twist Bioscience Price Performance

Shares of TWST Stock traded down $2.84 on Tuesday, hitting $51.07. The stock had a trading volume of 822,580 shares, compared to its average volume of 1,065,648. The business has a 50 day moving average of $40.69 and a 200 day moving average of $43.05. Twist Bioscience has a 12-month low of $25.07 and a 12-month high of $139.99. The stock has a market cap of $2.88 billion, a price-to-earnings ratio of -12.90 and a beta of 1.19.

Twist Bioscience (NASDAQ:TWST - Get Rating) last posted its quarterly earnings data on Friday, August 5th. The company reported ($1.08) EPS for the quarter, beating the consensus estimate of ($1.31) by $0.23. Twist Bioscience had a negative net margin of 112.91% and a negative return on equity of 29.61%. The firm had revenue of $56.10 million during the quarter, compared to analyst estimates of $52.06 million. During the same quarter last year, the business posted ($0.82) EPS. The company's revenue for the quarter was up 60.3% on a year-over-year basis. As a group, research analysts expect that Twist Bioscience will post -4.53 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of analysts have commented on TWST shares. Barclays boosted their price target on shares of Twist Bioscience from $45.00 to $55.00 and gave the company an "overweight" rating in a research note on Monday, August 8th. Robert W. Baird upped their target price on shares of Twist Bioscience from $43.00 to $56.00 in a report on Monday, August 8th. Finally, SVB Leerink lifted their price target on Twist Bioscience from $45.00 to $50.00 and gave the company a "market perform" rating in a research note on Monday, August 8th.

Insider Buying and Selling

In other Twist Bioscience news, CFO James M. Thorburn sold 6,620 shares of the company's stock in a transaction on Friday, May 20th. The stock was sold at an average price of $36.02, for a total value of $238,452.40. Following the completion of the transaction, the chief financial officer now owns 45,386 shares in the company, valued at approximately $1,634,803.72. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, insider William Banyai sold 1,275 shares of the company's stock in a transaction that occurred on Monday, May 23rd. The stock was sold at an average price of $37.04, for a total value of $47,226.00. Following the transaction, the insider now owns 259,926 shares in the company, valued at $9,627,659.04. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO James M. Thorburn sold 6,620 shares of the firm's stock in a transaction on Friday, May 20th. The stock was sold at an average price of $36.02, for a total value of $238,452.40. Following the completion of the sale, the chief financial officer now directly owns 45,386 shares of the company's stock, valued at $1,634,803.72. The disclosure for this sale can be found here. Over the last three months, insiders have sold 19,581 shares of company stock worth $654,504. 3.10% of the stock is owned by company insiders.

Receive TWST Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Twist Bioscience and its competitors with MarketBeat's FREE daily newsletter.

TWST Stock News Headlines

Twist Bioscience (NASDAQ:TWST) PT Raised to $56.00
10 Healthcare Stocks Making Moves After Earnings
Twist Bioscience Q3 Results Top Estimates
Twist Bioscience Earnings Preview
Twist Bioscience (TWST) to Release Quarterly Earnings on Friday
TWST Crosses Above Average Analyst Target
SNIA Announces DNA Data Storage Technology Affiliate
See More Headlines
Receive TWST Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Twist Bioscience and its competitors with MarketBeat's FREE daily newsletter.

TWST Company Calendar

Last Earnings
8/05/2022
Today
8/16/2022
Fiscal Year End
9/30/2022
Next Earnings (Estimated)
11/28/2022

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TWST
Fax
N/A
Employees
652
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$54.00
High Stock Price Forecast
$56.00
Low Stock Price Forecast
$50.00
Forecasted Upside/Downside
+5.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
4 Analysts

Profitability

Net Income
$-152,100,000.00
Net Margins
-112.91%
Pretax Margin
-118.54%

Debt

Sales & Book Value

Annual Sales
$132.33 million
Book Value
$11.78 per share

Miscellaneous

Free Float
54,617,000
Market Cap
$2.88 billion
Optionable
Not Optionable
Beta
1.19

Key Executives














TWST Stock - Frequently Asked Questions

Should I buy or sell Twist Bioscience stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Twist Bioscience in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" TWST shares.
View TWST analyst ratings
or view top-rated stocks.

What is Twist Bioscience's stock price forecast for 2022?

4 brokers have issued 12-month target prices for Twist Bioscience's stock. Their TWST share price forecasts range from $50.00 to $56.00. On average, they predict the company's share price to reach $54.00 in the next year. This suggests a possible upside of 5.7% from the stock's current price.
View analysts price targets for TWST
or view top-rated stocks among Wall Street analysts.

How have TWST shares performed in 2022?

Twist Bioscience's stock was trading at $77.39 on January 1st, 2022. Since then, TWST stock has decreased by 34.0% and is now trading at $51.07.
View the best growth stocks for 2022 here
.

When is Twist Bioscience's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 28th 2022.
View our TWST earnings forecast
.

How were Twist Bioscience's earnings last quarter?

Twist Bioscience Co. (NASDAQ:TWST) announced its quarterly earnings data on Friday, August, 5th. The company reported ($1.08) EPS for the quarter, beating the consensus estimate of ($1.31) by $0.23. The business had revenue of $56.10 million for the quarter, compared to the consensus estimate of $52.06 million. Twist Bioscience had a negative net margin of 112.91% and a negative trailing twelve-month return on equity of 29.61%. The company's quarterly revenue was up 60.3% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.82) EPS.

What guidance has Twist Bioscience issued on next quarter's earnings?

Twist Bioscience issued an update on its FY 2022 earnings guidance on Friday, August, 12th. The company provided EPS guidance of for the period. The company issued revenue guidance of $203.00 million-$203.00 million, compared to the consensus revenue estimate of $196.91 million.

What is Emily Leproust's approval rating as Twist Bioscience's CEO?

44 employees have rated Twist Bioscience Chief Executive Officer Emily Leproust on Glassdoor.com. Emily Leproust has an approval rating of 83% among the company's employees.

What other stocks do shareholders of Twist Bioscience own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Twist Bioscience investors own include CrowdStrike (CRWD), Pfizer (PFE), DocuSign (DOCU), Intel (INTC), NVIDIA (NVDA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), JD.com (JD), Tesla (TSLA) and Twilio (TWLO).

When did Twist Bioscience IPO?

(TWST) raised $75 million in an initial public offering on Wednesday, October 31st 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. J.P. Morgan and Cowen served as the underwriters for the IPO and Allen & Company and Baird were co-managers.

What is Twist Bioscience's stock symbol?

Twist Bioscience trades on the NASDAQ under the ticker symbol "TWST."

Who are Twist Bioscience's major shareholders?

Twist Bioscience's stock is owned by many different institutional and retail investors. Top institutional investors include ARK Investment Management LLC (11.14%), State Street Corp (6.77%), FMR LLC (6.34%), JPMorgan Chase & Co. (5.69%), William Blair Investment Management LLC (4.83%) and Sumitomo Mitsui Trust Holdings Inc. (4.76%). Insiders that own company stock include Bill Peck, Emily M Leproust, Emily M Leproust, James M Thorburn, Jan Johannessen, John P Molloy, Keith Crandell, Mark Daniels, Nicolas Barthelemy, Patrick John Finn, Patrick Weiss, Paula Green, Robert Chess and William Banyai.
View institutional ownership trends
.

How do I buy shares of Twist Bioscience?

Shares of TWST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Twist Bioscience's stock price today?

One share of TWST stock can currently be purchased for approximately $51.07.

How much money does Twist Bioscience make?

Twist Bioscience (NASDAQ:TWST) has a market capitalization of $2.88 billion and generates $132.33 million in revenue each year. The company earns $-152,100,000.00 in net income (profit) each year or ($3.96) on an earnings per share basis.

How many employees does Twist Bioscience have?

The company employs 652 workers across the globe.

How can I contact Twist Bioscience?

Twist Bioscience's mailing address is 681 GATEWAY BLVD., SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.twistbioscience.com. The company can be reached via phone at (800) 719-0671 or via email at maeve@argotpartners.com.

This page (NASDAQ:TWST) was last updated on 8/16/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.